Screener
Tango Therapeutics TNGX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accrued expenses and other liabilities | (8,690) | (6,124) |
| Operating lease liabilities | (781) | (780) |
| Deferred revenue | — | (5,392) |
| Net cash used in operating activities | (44,360) | (41,697) |
| Cash flows from investing activities | ||
| Purchase of property and equipment | 2 | (51) |
| Sales and maturities of marketable securities | 64,045 | 77,812 |
| Purchases of marketable securities | (54,412) | (47,164) |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's operating cash flow?
- Tango Therapeutics (TNGX) reported operating cash flow of -$44.36M in Q1 2026.
- How has Tango Therapeutics's operating cash flow changed year-over-year?
- Tango Therapeutics's operating cash flow decreased by 6.4% year-over-year, from -$41.7M to -$44.36M.
- What is the long-term trend for Tango Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Tango Therapeutics's operating cash flow has grown at a 23.6% compound annual growth rate (CAGR), from -$59.53M to -$138.89M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Tango Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude